In the last few decades, the pharmaceutical industry has experienced rapid growth in parenteral products, leading to easier availability of life-saving drugs in the market. The advances in sterile product formulations like protein-peptides, liposomes, suspensions, emulsions, and micro- and nanoparticles have modernised the design of drug delivery with better safety and efficacy.

New and advanced ideas have been presented for using prefilled syringes for improved safety, ease in usage, minimising errors in clinical use, and the ability for self-injections. Prefilled syringes have gained strong acceptance for the drug delivery of injectable drugs, especially in the treatment of chronic conditions that require repeated administration of the medications.

Almost half of the new drugs recently approved by the United States Food and Drug Administration (USFDA) are therapeutic proteins, and the drug-pipeline landscape is strongly shifting towards the same class of drugs. USFDA has recently approved Moderna’s bivalent mRNA vaccine to be used as a booster dose against COVID-19. In addition to mRNA, several cell & gene therapeutic agents such as ZYNTEGLO (betibeglogene autotemcel) by Bluebird bio Inc, CARVYKTI (ciltacabtagene autoleucel) by Janssen Biotech Inc, ZOLGENSMA (onasemnogene abeparvovec-xioi) by Novartis Gene Therapies, Inc. and others have also received the FDA approval for different products, these all are lifesaving treatments made available for patients.

The majority of gene therapy pharmaceuticals are administered directly into the affected area; henceforth, the utilisation of prefilled syringes (PFS) has been highly recognised in recent years.